TLDR Upadacitinib effectively treated a patient with multiple inflammatory conditions.
A patient with refractory Atopic Dermatitis (AD), Psoriasis (PsO), Psoriatic Arthritis (PsA), and Alopecia Areata (AA) was successfully treated with upadacitinib, a selective JAK-1 inhibitor. After failing multiple treatments, including ixekizumab and dupilumab, the patient achieved complete clearance of PsO, significant improvement in AA, and resolution of PsA and AD within three months of starting upadacitinib. This case underscores the potential of upadacitinib in managing complex inflammatory conditions and suggests the need for further clinical trials to explore its efficacy.
7 citations,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
3 citations,
December 2022 in “Cells” Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.
101 citations,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
